NEW BRUNSWICK, NEW JERSEY — Johnson & Johnson announced on Jan. 29 that its single-dose coronavirus vaccine was 66 percent effective in preventing moderate disease 28 days after injection in its Phase 3 global trials, according to a company press release.<br /><br />The company said the vaccine was 85 percent effective at preventing severe COVID, and that no one had died or was hospitalized 28 days following their vaccination.<br /><br />Like the AstraZeneca-Oxford vaccine and Russia's Sputnik V vaccine, and unlike Pfizer and Moderna's mRNA vaccines, Johnson & Johnson's vaccine uses a modified adenovirus as a vector.
